electroCore, Inc.ECOR

electroCore, Inc. filed its 10-Q for the quarter ended 31 March 2026 showing revenue of $9.6m while simultaneously announcing a net loss of $5.3m, an operating loss of $5.3m, and a negative shareholders’ equity of $-5.7m. Cash on hand stood at $4.9m, with operating cash burn of $-3.0m for the period. The company’s product line-gammaCore, Truvaga, Tac-Stim-is positioned as non-invasive vagus nerve stimulation technology aimed at challenging diseases, yet the financials read like a device start-up two pivots away from profitability. (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1560258/000149315226021495/form10-q.htm)

The filing notes that a portion of 2026 sales is expected to flow through a distribution agreement with Lovell Government Services and through government contract vehicles, including direct access via an existing FSS contract. The company also highlights that the number of VA facilities purchasing prescription gammaCore rose to 200 from 175, a detail that sounds more impressive until you notice it didn’t stop the red ink. Management states that expected cash requirements for the next twelve months ‘are based on the commercial success of our products’, which in plain English means the runway is tied to sales traction still unwritten. (source: 10-Q, https://www.sec.gov/Archives/edgar/data/1560258/000149315226021495/form10-q.htm)

The DEF 14A dated 20 July 2026 invites shareholders to a virtual meeting at www.virtualshareholdermeeting.com/ECOR2026, a URL that doubles as both investor access and inadvertent corporate art reflecting the current state of play. Inside the proxy, the board is thanked for its ‘industry experience,’ exemplified by a director who served at Spinecore until its 2004 sale to Stryker-a neat piece of résumé theatre that does not, in any way, fund the next payroll. The document is otherwise silent on near-term financing plans, share repurchases, or concrete paths to positive net income. (source: DEF 14A, https://www.sec.gov/Archives/edgar/data/1560258/000149315226033907/formdef14a.htm)

The company’s product page showcases gammaCore, Truvaga, and Tac-Stim as part of a non-invasive vagus nerve stimulation platform, but the evidence trail stops at ‘products acquired from NURO in May 2025’ and sales via government distribution. There is no filings-backed evidence of FDA approval expansions, pivotal trial readouts, or payer coverage milestones that would materially change the company’s risk profile. For now, the story is the gap between the polished platform description and the cash-burning balance sheet. (source: Our Products - gammaCore, Truvaga, Tac-Stim | electroCore, https://www.electrocore.com/product)

There is no chart rail supplied in the evidence; therefore no price or volume commentary is included here. The renderer may append TradingView links separately. (source: FreedomCore source manifest)